SALT LAKE CITY, April 14, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that the company has received clearance from the U.S. Food and Drug Administration (FDA) to market the MicroThermX® Microwave Ablation System (MicroThermX) for the specific indication of ablation procedures requiring partial or complete ablation of non-resectable liver tumors.
Perseon Director Damian E. Dupuy, M.D. commented, "This expanded indication for the MicroThermX gives hospitals and patients another option for the treatment of complicated non-resectable liver tumors using microwave ablation. The expanded clinical applications combined with the ease of use and attractive economics make the MicroThermX the leading microwave ablation product on the market today."
"A pillar of our strategic plan outlined earlier this year is to make Perseon more clinically relevant through clinical data and expanded indications to fight humanity's worst disease – cancer, and we continue to execute on our strategic plan," said Clint Carnell, CEO of Perseon. "The recent appointment of Brian Meltzer, M.D. as Chief Medical Officer, our announcement last week about our new indication for laparoscopic ablation, and the expanded indication for non-resectable liver tumors all demonstrate outstanding clinical momentum and business execution in expanding the market for our ablation products."
Perseon Corporation, formerly BSD Medical Corporation, invests its resources in fighting humanity's worst disease: cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver microwave ablation solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused microwave energy, expanding the options and broadening the opportunities for cancer treatment.
Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Tricia Ross Financial Profiles 310-622-8226 email@example.com